Skip to main content
Premium Trial:

Request an Annual Quote

BeadArray, Lucidea Universal ScoreCard


Illumina of San Diego has developed a set of more than 2,300 assayed SNP markers for its fiber optic stalk-based BeadArray platform. The SNP set will be available as a linkage analysis study tool for Illumina’s genotyping service customers, the company said. The markers were assembled from the SNP Consortium panel, in addition to new loci that Illumina has discovered. The company then tested and optimized the set for accuracy and multiplex assay performance.

Illumina also said it had ramped up its genotyping capabilities. “Concurrent with the development of our new linkage panel, we have scaled our assay technology to levels exceeding 1,000 multiplexed loci — starting in sample preparation and continuing through amplification and analysis — while obtaining accuracy levels above 99 percent,” Jay Flatley, Illumina’s president and CEO, stated.


Amersham Biosciences has introduced the Lucidea Universal ScoreCard reagent kit, which is designed for the validation and normalization of microarray data. The kit provides controls in defined concentrations and is intended for correlation between signal intensities and the units of mRNA. “We designed these controls to be independent of species, sample type, and deposition platform,” said Michael Pettigrew, vice president of marketing, genomics. “This cross-platform control capability will allow the microarray market to take the first important steps toward standardization.”

Each kit includes ten calibration controls packaged in individual tubes, and eight controls in low to high expression levels; as well as an mRNA spike mix, which includes 18 mRNA controls, two negative controls, and three utility controls for use at various stages of sample preparation. There are three sizes of kits, one for 20 hybridizations, one for 200 hybridizations, and one for 1,000 experiments.


The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.